Compare Novo Nordisk A/S (NVO) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Novo Nordisk A/S trades at $45.08 (market cap $198.57B), while iShares 20 Plus Year Treasury Bond ETF trades at $81.49. The key difference: Novo Nordisk A/S pays a 4.03% dividend while iShares 20 Plus Year Treasury Bond ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| NVO | TLT | |
|---|---|---|
Market Cap | $198.57B | — |
Sector | Health | — |
52-Week High | $63.98 | $92.06 |
52-Week Low | $35.29 | $81.35 |
Enterprise Value | $213.37B | — |
Dividend Yield | 4.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
TLT trades at $82.20, down slightly by 0.01% with a bearish technical signal from moving averages. The ETF faces headwinds from rising Treasury yields and potential large-scale selling by institutional investors like Norway's sovereign wealth fund. Recent Treasury buyback announcements of up to $6 billion in long-dated debt provide some support, but the overall trend remains challenging amid inflation concerns and rising oil prices.
The outlook for TLT remains cautious as rising interest rates and inflation pressures continue to weigh on long-duration bonds. While current RSI levels suggest potential oversold conditions, the fundamental environment of higher yields and potential institutional selling creates significant downside risk. Investors should monitor Treasury policy actions and global bond market developments closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
